Paper
N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide; one of a class of novel benzenesulphonamides which are orally-active, ETA-selective endothelin antagonists
Published Jun 3, 1997 · A. Mortlock, C. Bath, R. Butlin
Bioorganic & Medicinal Chemistry Letters
UNKNOWN SJR score
5
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide is a novel ETA-selective endothelin antagonist with high affinity
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
Halogen substitution at the isoxazole ring enhances the activity of N-(isoxazolyl)sulfonamide endothelin antagonists
Halogen substitution at the isoxazole ring significantly enhances the activity of N-(isoxazolyl)sulfonamide endothelin antagonists, increasing binding affinity for both ET A and ET B receptors.
1996·13citations·M. Chan et al.·Bioorganic & Medicinal Chemistry Letters
Bioorganic & Medicinal Chemistry Letters
Does Endothelin‐1 Play a Role in the Pathogenesis of Cerebral Vasospasm?
Endothelin-1 may play a role in the pathogenesis of cerebral vasospasm following subarachnoid hemorrhage, but its role in narrowing cerebral arteries exposed to autologous blood remains controversial.
1994·73citations·F. Cosentino et al.·Stroke
Stroke
Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist
Endothelin-1 plays a significant role in cardiovascular diseases, as revealed by the first orally active endothelin receptor antagonist, Ro 46-2005.
1993·501citations·M. Clozel et al.·Nature
Nature
Use of the endothelin antagonists BQ‐123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF
ETA receptors mediate smooth muscle contractions, while ETB receptors mediate vasodilation, with SX6c being more potent in contracting the rat stomach strip.
1993·189citations·T. Warner et al.·British Journal of Pharmacology
British Journal of Pharmacology
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.
Pulmonary hypertension is associated with increased expression of endothelin-1 in vascular endothelial cells, suggesting that local production of endothelin-1 may contribute to vascular abnormalities in this disorder.
1993·1877citations·A. Giaid et al.·The New England journal of medicine
The New England journal of medicine
The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo.
The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo, with sarafotoxin S6C causing a temporary decrease in blood pressure followed by a long-lasting pressor response and indirect renal and mesenteric vaso
1992·432citations·Martine Clozel et al.·Biochemical and biophysical research communications
Biochemical and biophysical research communications
Venous smooth muscle contains vasoconstrictor ETB-like receptors.
Vascular smooth muscle cells express both ET A and ET B receptors, and stimulation of either subtype can result in force development.
1992·262citations·Suzanne Moreland et al.·Biochemical and biophysical research communications
Biochemical and biophysical research communications
The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis.
The selective endothelin ETA receptor antagonist BQ123 selectively inhibits endothelin-1-mediated mitogenesis in vascular smooth muscle cells, demonstrating that ET-1-mediated mitogenesis in vascular smooth muscle is mediated by ET A receptors.
1992·148citations·E. Ohlstein et al.·European journal of pharmacology
European journal of pharmacology
Endothelin and structurally related analogs distinguish between endothelin receptor subtypes.
Endothelin receptor subtypes differ in rat aorta and rabbit pulmonary artery, with a potential new subtype in rat left atria.
1992·87citations·Robert Panek et al.·Biochemical and biophysical research communications
Biochemical and biophysical research communications
Citations
The Discovery of Macitentan - A Standard Medicinal Chemistry Program?
Macitentan's discovery was driven by tailoring a medicinal chemistry program to optimize in vivo efficacy and safety, leading to a potent dual endothelin receptor antagonist for treating pulmonary arterial hypertension.
2017·1citation·M. Bolli·Chimia
Chimia
Benzimidazole-5-sulfonamides as novel nonpeptide luteinizing hormone releasing hormone (LHRH) antagonists: minimization of mechanism-based CYP3A4 inhibition.
Novel, potent non-peptide LHRH antagonists have been developed, minimizing CYP3A4 inhibition while maintaining potent antagonist activity.
2005·2citations·Kentaro Hashimoto et al.·Chemical & pharmaceutical bulletin
Chemical & pharmaceutical bulletin